11:32 AM EDT, 07/25/2024 (MT Newswires) -- ScPharmaceuticals ( SCPH ) said Thursday that the US Food and Drug Administration has accepted for filing its supplemental new drug application to expand the Furoscix indication to include edema treatment due to fluid overload in patients with chronic kidney disease.

The FDA has set March 6, 2025, as a prescription drug user fee act target action date, the company said.

Furoscix is indicated to treat congestion due to fluid overload in adult patients with certain chronic heart failure.

ScPharmaceuticals ( SCPH ) shares were up 3% in recent trading.

Price: 4.98, Change: +0.14, Percent Change: +2.98